Landscape of helper and regulatory antitumour CD4+ T cells in melanomaGiacomo Oliveira, Catherine J. Wu, David A. Braun et al.|Nature|2022Cited by 192
Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti–PD-1 in head and neck cancerGiacomo Oliveira, Ravindra Uppaluri, Ann Marie Egloff et al.|Science Immunology|2023Cited by 118
Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settingsJacqueline S. Garcia, Robert J. Soiffer, Yael Flamand et al.|Blood|2022Cited by 51
Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid diseaseLivius Penter, Catherine J. Wu, Yang Liu et al.|Blood|2023Cited by 51
A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphomaReid W. Merryman, Caron A. Jacobson, Robert Redd et al.|Annals of Hematology|2023Cited by 7